BMS-986171 / BMS - LARVOL DELTA

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. (PubMed, Int J Mol Sci) - "A CCR2/5 inhibitor (BMS-687681-02-020) and a pegylated FGF21 agonist (BMS-986171) were tested in male C57BL/6J mice subjected to dietary models of NASH and fibrosis (choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) up to 12 weeks; short- (2w) or long-term (6w) treatment). (4) CCR2/5 inhibition blocks hepatic infiltration of inflammatory monocytes, FGF21 agonism improves obesity-related metabolic disorders. Combined therapy ameliorates steatohepatitis and fibrosis more potently than single drug treatment in rodent NASH, corroborating the therapeutic potential of combining these two approaches in NASH patients."

Journal • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity • CCL2 • FGF21

[VIRTUAL] Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergises in ameliorating steatohepatitis and fibrosis (EASL-ILC-I 2020) - "We tested a CCR2/5 antagonist (BMS-687681, 45 mpk bid PO or 15 mpk bid in combination) and/or a PEG-FGF21 variant (PEGFGF21v, BMS-986171, 0.6 mpk biw SC) in male C57BL/6J mice, subjected to either acute liver injury (single carbon tetrachloride injection, CCl4) or chronic steatohepatitis and fibrosis (choline-deficient, L-amino acid-defined high-fat diet (CDAHFD) for up to 12 weeks). CCR2/5 antagonism blocks inflammatory monocytes infiltration, and treatment with an FGF21 analogue has beneficial effects on metabolism and pathogenic drivers of NASH and fibrosis. Combined therapy ameliorates progressive steatohepatitis and fibrosis more effectively than single drug treatment, corroborating the therapeutic potential of combining these two approaches in patients with advanced NASH."

Combination therapy • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • Liver Failure • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • CCL2 • CCL4 • FGF